Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas.

Huber, Markus; Luedi, Markus M; Schubert, Gerrit A; Musahl, Christian; Tortora, Angelo; Frey, Janine; Beck, Jürgen; Mariani, Luigi; Christ, Emanuel; Andereggen, Lukas (2022). Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas. Frontiers in endocrinology, 13, p. 810219. Frontiers Research Foundation 10.3389/fendo.2022.810219

[img]
Preview
Text
fendo-13-810219.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (4MB) | Preview

Background

First-line surgery for prolactinomas has gained increasing acceptance, but the indication still remains controversial. Thus, accurate prediction of unfavorable outcomes after upfront surgery in prolactinoma patients is critical for the triage of therapy and for interdisciplinary decision-making.

Objective

To evaluate whether contemporary machine learning (ML) methods can facilitate this crucial prediction task in a large cohort of prolactinoma patients with first-line surgery, we investigated the performance of various classes of supervised classification algorithms. The primary endpoint was ML-applied risk prediction of long-term dopamine agonist (DA) dependency. The secondary outcome was the prediction of the early and long-term control of hyperprolactinemia.

Methods

By jointly examining two independent performance metrics - the area under the receiver operating characteristic (AUROC) and the Matthews correlation coefficient (MCC) - in combination with a stacked super learner, we present a novel perspective on how to assess and compare the discrimination capacity of a set of binary classifiers.

Results

We demonstrate that for upfront surgery in prolactinoma patients there are not a one-algorithm-fits-all solution in outcome prediction: different algorithms perform best for different time points and different outcomes parameters. In addition, ML classifiers outperform logistic regression in both performance metrics in our cohort when predicting the primary outcome at long-term follow-up and secondary outcome at early follow-up, thus provide an added benefit in risk prediction modeling. In such a setting, the stacking framework of combining the predictions of individual base learners in a so-called super learner offers great potential: the super learner exhibits very good prediction skill for the primary outcome (AUROC: mean 0.9, 95% CI: 0.92 - 1.00; MCC: 0.85, 95% CI: 0.60 - 1.00). In contrast, predicting control of hyperprolactinemia is challenging, in particular in terms of early follow-up (AUROC: 0.69, 95% CI: 0.50 - 0.83) vs. long-term follow-up (AUROC: 0.80, 95% CI: 0.58 - 0.97). It is of clinical importance that baseline prolactin levels are by far the most important outcome predictor at early follow-up, whereas remissions at 30 days dominate the ML prediction skill for DA-dependency over the long-term.

Conclusions

This study highlights the performance benefits of combining a diverse set of classification algorithms to predict the outcome of first-line surgery in prolactinoma patients. We demonstrate the added benefit of considering two performance metrics jointly to assess the discrimination capacity of a diverse set of classifiers.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic and Policlinic for Anaesthesiology and Pain Therapy
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurosurgery

UniBE Contributor:

Huber, Markus, Lüdi, Markus, Beck, Jürgen

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1664-2392

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Pubmed Import

Date Deposited:

08 Mar 2022 10:49

Last Modified:

05 Dec 2022 16:13

Publisher DOI:

10.3389/fendo.2022.810219

PubMed ID:

35250868

Uncontrolled Keywords:

dopamine agonists long-term outcome machine learning prediction modeling primary surgical therapy prolactinoma

BORIS DOI:

10.48350/166748

URI:

https://boris.unibe.ch/id/eprint/166748

Actions (login required)

Edit item Edit item
Provide Feedback